# A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

Source: https://onco.cc/trials/nct06472076/  
OnCo record `nct06472076` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dostarlimab and Pembrolizumab in non-small-cell lung cancer, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT06472076 by GlaxoSmithKline, with 88 participants enrolled, started 2024-06-10 and due to reach its primary completion in 2026-06-30. Interventions recorded: Dostarlimab, Belrestotug, Pembrolizumab and Placebo.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06472076
- Phase: 3
- Setting: A Randomized, Multicenter, Double-blind, Phase 3 Study to Investigate the Safety and Efficacy of Belrestotug in Combination With Dostarlimab Compared With Placebo in Combination With Pembrolizumab in Participants With Previously Untreated, Unresectable, Locally Advanced or Metastatic PD-L1 Selected Non-small Cell Lung Cancer (GALAXIES Lung-301)
- Sponsor: GlaxoSmithKline
- Enrolled: 88

## Sources

- ClinicalTrials.gov NCT06472076: https://clinicaltrials.gov/study/NCT06472076

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct06472076.json